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Abstract
Human dental pulp stem cells (DPSCs) can differentiate to a wide range of different
cell lineages, and share some gene expression and functional similarities with
pluripotent stem cells. The stemness of DPSCs can also be pharmacologically
enhanced by the activation of canonical Wnt signaling. Here, we examined the
metabolic profile of DPSCs during reprogramming linked to Wnt activation, by a short
(48 hr) exposure to either the GSK3‐β inhibitor BIO (6‐bromoindirubin‐3´‐oxine) or
human recombinant protein WNT‐3A. Both treatments largely increased glucose
consumption, and induced a gene overexpression of pyruvate and mitochondrial
acetyl‐coA producing enzymes, thus activating mitochondrial tricarboxylic acid cycle
(TCA) metabolism in DPSCs. This ultimately led to an accumulation of reducing power
and a mitochondrial hyperpolarization in DPSCs. Interestingly, Nile Red staining
showed that lipid fuel reserves were being stored in Wnt‐activated DPSCs. We
associate this metabolic reprogramming with an energy‐priming state allowing DPSCs
to better respond to subsequent high demands of energy and biosynthesis
metabolites for cellular growth. These results show that enhancement of the
stemness of DPSCs by Wnt activation comes along with a profound metabolic
remodeling, which is distinctly characterized by a crucial participation of mitochon-
drial metabolism.
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1 | INTRODUCTION
Dental pulp stem cells (DPSCs) constitute a very promising tool for
regenerative medicine procedures. These stem cells can differentiate
to very diverse cell lineages, and have been successfully used in
different experimental animal models of pathology (Hollands,
Aboyeji, & Orcharton, 2018), as well as in several clinical trials to
regenerate oral and dental tissues in humans (Giuliani et al., 2013;
Nakashima et al., 2017). DPSCs have a high clonogenic potential with
a distinct ectomesenchymal neural crest (NC) phenotype (Gronthos
et al., 2002; Gronthos, Mankani, Brahim, Robey, & Shi, 2000), which
endows them with the capacity to form not only mesenchymal
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lineage cells such as adipocytes, osteoblasts, odontoblasts, and
chondrocytes, but also neurons, Schwann cells (Gervois et al.,
2015; Martens et al., 2014), smooth muscle, vascular endothelial
cells, and among others (Karbanová et al., 2011).
Reprogramming and generating pluripotent stem cells out of
somatic cells remains a promising alternative to obtain autologous
differentiated cells for graft therapies. However, current reprogram-
ming methods often rely on permanent genetic modification, precluding
their use for human medical therapy. Interestingly, DPSCs have also
been described to show a pluripotent‐like phenotype (Atari et al., 2012)
and a high plasticity for cell reprogramming, even using mild methods
which do not involve gene transfection, making them a promising
alternative source of pluripotent‐like cells (Atari et al., 2011; Pisal et al.,
2018; Uribe‐Etxebarria et al., 2017; Yan et al., 2010).
Stem cell differentiation and/or somatic cell reprogramming are
characterized by profound changes in cell metabolism. Over the last
few years, increasing experimental evidence pictures metabolism as a
key regulator of both stem cell potency and differentiation (Hanahan
& Weinberg, 2011; Pavlova & Thompson, 2016; Zhang et al., 2016b).
This metabolic priming is suited to respond to the demands of cell
growth and proliferation (Lunt & Vander Heiden, 2011). Important
evidence also links stemness to mitochondrial dynamics and protein
homeostasis (García‐Prat, Sousa‐Victor, & Muñoz‐Cánoves, 2017).
There exist two major metabolic states of the cell: Aerobic/oxidative
(occurring in the mitochondria) and anaerobic/glycolytic (occurring in
the cytosol), which perform at least three essential functions: (1) The
generation of the energy (ATP) and reducing power (NADH, FADH2,
and NADPH) necessary for biosynthesis processes; (2) the produc-
tion of glycolytic intermediates essential for anabolic reactions
during cell division; and (3) the release of metabolites used in
enzymatic reactions, including those involved in epigenetic modifica-
tion (Teslaa & Teitell, 2015).
Compelling evidence shows that the specific metabolic require-
ments of pluripotent stem cells tip the balance towards a higher
utilization of anaerobic pathways, at the expense of a reduced
utilization of aerobic oxidative phosphorylation, which in turn
associates with the process of cell differentiation (Chandel, Jasper,
Ho, & Passegue, 2016; Mathieu & Ruohola‐Baker, 2017). Inducing the
transition from oxidative into glycolytic metabolism promotes
somatic cell reprogramming to iPSCs (Folmes et al., 2011; Gu et al.,
2016). Stemness is promoted, and differentiation is prevented by
glycolysis induction or oxidative metabolism inhibition (Mathieu &
Ruohola‐Baker, 2017; Varum et al., 2011) whereas differentiation of
iPSCs occurs through oxidative metabolism, which is characterized
by a high ATP and low‐lactate content (Cho et al., 2006; Folmes et al.,
2011; Varum et al., 2011). However, despite these findings,
controversy remains about the precise role of mitochondrial
oxidative metabolism in the early onset of pluripotency. There is
also evidence for a transient mitochondrial oxidative phosphorylation
burst during the initial stages after nuclear reprogramming (Hawkins
et al., 2016; Kida et al., 2015).
Here, we report that a deep metabolic remodeling occurs in
DPSCs during the first 48 hr of reprogramming under Notch and Wnt
signaling modulation conditions, which were previously described to
regulate the expression of pluripotency core factors and self‐renewal
in these cells (Uribe‐Etxebarria et al., 2017). This study gives
evidence of a metabolic switch, distinctly characterized by a
mitochondrial involvement in the generation of large amounts of
reducing power, and a cytoplasmic accumulation of lipid fuel
reserves, associated with an enhanced DPSC stemness. Combinator-
ial modulation of signaling pathways reveals cell‐type‐specific
requirements for a highly efficient and synchronous reprogramming
to iPSCs (Vidal, Amlani, Chen, Tsirigos, & Stadtfeld, 2014). Therefore,
the present study provides very interesting new data with regard to
approachable future research to design new protocols for a safe
DPSC reprogramming.
2 | MATERIALS AND METHODS
2.1 | DPSC culture
DPSCs were isolated from human third molars obtained from healthy
donor patients between 15 and 30 years of age by fracture and
enzymatic digestion of the pulp tissue for 1 hr at 37°C with 3mg/ml
collagenase (Thermo Fisher Scientific Cat# 17018‐029, Boston, MA)
and 4mg/ml dispase (Thermo Fisher Scientific Cat# 17105‐041)
followed by mechanical dissociation. Cells were cultured in Dulbec-
co's Modified Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), L‐glutamine (1mM), and the antibiotics penicillin
(100 U/ml) and streptomycin (150 µg/ml). The DPSCs could be
amplified and maintained in these conditions for very long periods
( > 6 months). However, to avoid cell aging issues, we only used
DPSCs that had been grown in culture for less than 3 months and had
accumulated no more than six total passages. Comparative experi-
ments between control and treatment conditions were always and
without exception performed in parallel using DPSCs from the same
donor.
2.2 | Notch and wnt pathway pharmacological
modulation
To inhibit Notch signaling pathway, we used DAPT (N‐[N‐(3,5‐
difluorophenacetyl)‐L‐alanyl]‐S‐phenylglycine t‐butyl ester), a γ‐se-
cretase inhibitor, (Calbiochem Cat#565784, San Diego, CA), at a
concentration of 2.5 µM. DAPT was added to the culture medium for
48 hr before the assays where DAPT‐treated DPSCs were compared
with DPSCs treated only with the control vehicle, 2.5 µM dimethyl-
sulfoxide (DMSO). To overactivate Wnt signaling pathway, we used
2.5 µM BIO (6‐bromoindirubin‐3´‐oxine), a GSK3β inhibitor (Calbio-
chem Cat#361550), which was added to the medium for 48 hr before
the assays. BIO‐treated cells were compared with DPSCs exposed to
the inactive analog MBIO (methyl‐6‐bromoindirubin‐3´‐oxine) at
2.5 µM as a corresponding control (Calbiochem Cat#361556).
WNT‐3A recombinant protein (R&D Systems Cat#5036‐WN‐010,
Minneapolis) was also added to the DPSC cultures to overactivate
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Wnt signaling, at a concentration of 2.5 µM during a total incubation
time of 48 hr, as in the rest of the treatments.
2.3 | 1H‐NMR of DPSCs
To obtain an NMR spectrum, an average of 6 × 106 cells was extracted
using the dual phase extraction method (Al‐Saffar et al., 2006).
Lyophilized samples of the water soluble fraction were reconstituted
in deuterium oxide (D2O).
1H‐NMR spectra were acquired as previously
described (Al‐Saffar et al., 2006). Metabolite concentrations were
determined by integration and normalized relative to the peak integral
of an internal reference (TSP 0.15%) and corrected for the number of
cells extracted per sample.
2.4 | RNA extraction, conventional RT‐PCR, and
quantitative Real‐Time PCR (qPCR)
Total RNA was extracted from the cells using the RNeasy Kit (Qiagen
Cat# 74104, Hilden, Germany) and checked for purity by calculating
the 260/280 ratio via the Nanodrop Synergy HT (Biotek, Winooski,
VT). Complementary DNA (cDNA; 50 ng/µl) was obtained by reverse
transcription of total extracted RNA using the iScript cDNA Kit
(BioRad Cat# 1708890, Hercules, CA) with the following reagents:
iScript reverse Transcriptase (1 µl), 5x iScript Reaction Mix (4 µl), and
nuclease free water (variable) to a final volume of 20 µl. We analyzed
gene expression using 1 µl of cDNA (5 ng/µl) diluted in 4 µl of My
TaqTM Red Mix (Bioline Cat#BIO‐25043, St. Petersburg, Russia), 1 µl
of primers (0.625 µM), and nuclease free water for a total volume
reaction of 10 µl, for conventional real‐time polymerase chain
reaction (RT‐PCR). Amplification products were separated by
electrophoresis in a 2% agarose gel. Quantitative real‐time PCR
(qRT‐PCR) experiments were conducted in an iCyclerMyiQTM Single‐
Color Real‐Time PCR Detection System (BioRad), using 4.5 µl of
Power SYBR® Green PCR Master Mix 2 × (Applied BiosystemsTM,
Cat# 4367659, Carlsbad, CA), 0.5 µl of primers (0.3125 µM), 0.3 µl of
cDNA (1.5 ng/µl), and nuclease free water for a total volume reaction
of 10 µl. The primer pairs for different genes were obtained from
public databases, and validated via the Primer‐Blast method. All
oligonucleotide primers were purchased from Sigma Aldrich and
checked for optimal efficiency ( > 90%) in the qPCR reaction under
our experimental conditions. The relative expression of each gene
was calculated using the standard 2−ΔCt method (Livak & Schmittgen,
2001) normalized with respect to the average between β‐ACTIN and
GAPDH as internal controls. All reactions were performed in
triplicate. qPCR was run on ABI PRISM® 7000 (Thermo Fisher
Scientific, Boston, MA). Data were processed by CFX Manager™
Software (BioRad). We assessed that all qPCR reactions yielded only
one amplification product by the melting curve method.
2.5 | Immunoblotting
The cells were washed with 0.9% NaCl several times and the proteins
were extracted with 100 µl of Lysis Buffer (50mM Tris‐HCl pH 7.5,
1 mM ethylenediaminetetraacetic acid (EDTA), 150mM NaCl, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1%
IGEPAL® CA‐630 in dH2O, and Proteinase Inhibition Cocktail Set
III 1:100, Calbiochem Cat#539134,). Protein quantification was
performed in each western blot using the DCTM Protein Assay
(BioRad Cat#5000112), including Reagent A (#500‐0113), Reagent B
(#500‐0114), and Reagent S (#500‐0115).
The samples were diluted in NuPAGE sample buffer (Novex, Life
technologies, Cat#NP0007, Carlsbad, CA) and loaded onto a 4–12%
Invitrogen NuPAGE Bis Tris Gel (1mm x 10 well; Novex,
Cat#NP032180X, Life Technologies) followed by transfer onto
0.45 µm‐pore nitrocellulose membranes (Inmmobilon® Transfer
Membranes; EMD Millipore) and run in an XCell Sure Lock
Electrophoresis machine (Novex, Cat#NP0007, Life Technologies).
For western blot analyses, we used anti β‐ACTIN antibody (1:1,000,
Cell Signaling Technology Cat# 4967, RRID:AB_330288), anti‐GAPDH
antibody (1:10,000, Millipore Cat# MAB374, RRID:AB_2107445, MO),
anti‐lactate dehydrogenase A (LDH‐A) antibody (1:10,000, Santa Cruz
Biotechnology Cat# sc‐27230, RRID:AB_672142, TX), anti‐lactate
dehydrogenase B (LDH‐B) antibody (1:1,000, Thermo Fisher Scientific
Cat# PA5–43141, RRID:AB_2609663), and anti‐Hexokinase 2 (HK2)
antibody (1:1,000, Cell Signaling Technology Cat# 2106S, RRID:
AB_823520). The secondary antibodies antirabbit and antimouse (GE
Healthcare Cat# NA9340‐1ml, RRID:AB_772191, UK; Dako Cat#
P0260, RRID:AB_2636929, Hovedstaden, Denmark) were added at a
1:2,000 dilution. The membranes were stripped using Red Blot
(Inmmobilon® EMD Millipore M Cat# 2504).
2.6 | Nile red assay of cellular lipid content
DPSCs cultured over glass coverslips were fixed with 4% parafor-
maldehyde for 10min and washed with phosphate‐buffered saline
(PBS). The DPSCs were then incubated for 15min with 1 µg/ml Nile
Red (Thermo Fisher Scientific, Cat#N1142, Waltham, MA) diluted in
PBS, followed by DAPI which was used to counterstain cell nuclei.
Images were captured with an epifluorescence Axioskop microscope
(Zeiss, Germany) with a Nikon NIS‐Elements and an Apotome
Confocal Microscope (Zeiss, Germany) operated with Nikon
DS‐Qi1Mc software (Tokyo, Japan). The fluorescence intensities in
the samples were quantified by Fiji‐ImageJ (Schindelin et al., 2012)
after background subtraction.
2.7 | Cell viability, mitochondrial membrane
potential, and reactive oxygen species assays
We used Calcein‐AM (5 µM, Thermo Scientific Cat#C3100MP) to
detect cell presence and viability and Tetra Methyl Rhodamine Ethyl‐
ester, or TMRE (200 nM, Thermo Fisher Scientific Cat#T669) to
provide an estimation of the mitochondrial membrane potential of
DPSCs. In addition, we used 2,7‐dichlorofluorescein diacetate or
DC‐FDA (100 µM, Thermo Fisher Scientific Cat#D399) to evaluate
the production of reactive oxygen species (ROS) by DPSCs. As a
positive control for ROS production we used 0.1%, 0.5%, and 1.5% of
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H2O2. In these experiments, DAPI was also included as a nuclear
counterstain. We incubated DPSCs with fluorescent dyes for 30min
at 37°C in culture medium and washed the cells three times with
PBS. Fluorescence quantification was accomplished using micro-
fluorimetry by measuring light emission at 495 nm (Calcein‐AM;
green fluorescence), 630 nm (PI; red fluorescence), 527 nm (DCF‐DA;
green fluorescence), and 359 nm (DAPI; blue fluorescence) in a
Fluoroskan Ascent plate reader (Thermo Scientific). Data are plotted
as normalized mean ± SEM of TMRE/Calcein and mean ± SEM of DCF‐
DA/DAPI fluorescence to compensate for differences in cell density
in the reading field.
2.8 | Alamar blue detection
Alamar Blue (Thermo Fisher Scientific Cat#DAL1025) was used to
detect cell viability and estimate the cellular reducing power of
DPSCs. Alamar Blue was diluted 1:10 and absorbance was read at
600 nm (reduced state) in a Fluoroskan Ascent plate reader or in a
Nanodrop Synergy HT (Biotek) run with Microplate Software: BioTek
Gen5 Data Analysis Software (Biotek).
2.9 | NAD+/ NADH detection kit
This assay was performed using a NAD+/NADH Kit (Sciencell Research
Laboratories, Cat#8368, Carlsbad, CA). Previously, nonspecific proteins
of the DPSC samples were eliminated by an Amicon Ultra‐0.5
Centrifugal Filter Unit with Ultracel‐10 membrane (Millipore Ca-
t#UFC501008). Absorbance was measured at 490 nm with an ELISA
plate reader in Nanodrop Synergy HT (Biotek) with Microplate
Software: BioTek Gen5 Data Analysis Software (Biotek). The NAD/
NADH ratio was calculated following the manufacturer's instructions.
2.10 | Statistical analyses
Statistical analyses were performed with Microsoft Excel, IBM SPSS
Statistics v.9 (SPSS, Chicago, IL) and Graph Pad v.6 software (Graph Pad
Inc., San Diego, CA). All data sets were subjected to a Kolmogorov–
Smirnov normality test before analysis. For small sample sizes
nonparametric tests were chosen by default. Comparisons between
only two groups were made using U‐Mann Whitney test. Comparisons
between multiple groups were made using Kruskal–Wallis followed by
Dunn´s post hoc test. The p ≤0.05 was considered to be statistically
significant.
3 | RESULTS
3.1 | Notch activity is required for the maintenance
of glycolytic metabolism of DPSCs
In a previous report (Uribe‐Etxebarria et al., 2017), it was characterized
that Notch inhibition by the DAPT treatment (2.5 µM for 48 hr)
decreased stemness of DPSCs. Here, we wanted to assess whether
such inhibition induced also changes at the metabolic level by assessing
the presence of cellular metabolites using nuclear magnetic resonance
(NMR). Thus, it was found that DAPT significantly affected the levels of
intracellular lactate (54%±15%; p=0.002), glucose (164%±13%;
p=0.037), and glycerophosphocoline or GPC (57.5%±12.6%; p =0.04)
in DPSCs (Figure 1a). Following DAPT treatment, glucose was more
accumulated in DPSCs, whereas the levels of lactate were found to be
significantly lower than in control samples. The levels of amino acids
(glutamate and glutamine), and metabolites involved in membrane
phospholipid turnover (choline, phosphocholine PC, and GPC) were
either not affected or decreased in DPSCs after the DAPT treatment
(Figure 1a). In addition, transcript messenger RNA (mRNA) expression
analysis for some key protein enzymes of the glycolytic and
F IGURE 1 Notch inhibition by DAPT affects glycolytic
metabolism in DPSCs. (a) NMR analysis revealed differences in the
levels of lactate, GPC, and glucose following DAPT exposure.
(b) Q‐PCR analysis confirmed a decrease in HK2, LDHA, LDHB,
SLG16A1, PDHB, and CPT1A expression between control (DMSO)
and DAPT conditions. Data are normalized to reference β‐ACTIN and
GAPDH levels and presented as the mean + SEM (n = 6). The dashed
line represents normalized gene expression to control conditions. (c)
Representative WB showing LDHA, LDHB, and HK2. β‐ACTIN was
used as protein loading control. *p < 0.05; **p < 0.01; ***p < 0.001.
U‐Mann Whitney test. DAPT, N‐[N‐(3,5‐difluorophenacetyl)‐L‐
alanyl]‐S‐phenylglycine t‐butyl ester; DMSO, dimethylsulfoxide;
DPSCs, dental pulp stem cells; GPC, glycerophosphocoline; NMR,
nuclear magnetic resonance; q‐PCR, quantitative polymerase chain
reaction
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mitochondrial metabolism hexokinase 2 (HK2) and pyruvate dehydro-
genase B and X (PDHB, PDHX) were all found to be negatively affected
by the exposure to DAPT (Figure 1b). Both the expression of the
mitochondrial fatty acid carrier CPT1A (carnitine palmitoyltransferase)
and the plasma membrane monocarboxylate transporter SLC16A1/
MCT1 were found to be downregulated at mRNA level when the DPSCs
were treated with DAPT (Figure 1b). Lactate dehydrogenase A (LDHA)
and lactate dehydrogenase B (LDHB) gene expression levels also
underwent a decrease of more than 50% with respect to the control
conditions (Figure 1b). Finally, WB also confirmed these changes, where
LDHA, LDHB, and HK2 had a consistently reduced expression also at the
protein level in DPSCs (Figure 1c).
3.2 | BIO‐induced Wnt activation increases glucose
utilization and the expression of genes promoting
mitochondrial TCA activity and lipid biosynthesis in
DPSCs
To investigate whether Wnt/β‐catenin activation would affect meta-
bolism in DPSCs, we used a 2.5 µM BIO treatment of 48 hr to
overactivate Wnt signaling by inhibiting β‐catenin degradation, as this
had been previously associated to an increase in DPSC stemness
(Uribe‐Etxebarria et al., 2017). By NMR, we observed that treatment
with BIO induced a significant reduction in the levels of glucose
(14.2%± 2.2%; p = 0.037), and glutamine (41.4%± 9.1%; p = 0.002) and
increased the cellular amount of GPC (240.7%± 66.9%; p = 0.037;
Figure 2a). In addition, Wnt activation also induced the overexpression
of several genes involved in: (1) Glycolysis, pyruvate kinase isozymeM2
(PKM2); (2) mitochondrial acetyl‐coA biosynthesis, pyruvate dehydro-
genase B (PDHB); (3) cytosolic acetyl‐coA biosynthesis, ATP‐citrate
lyase (ACLY); and (4) cytosolic fatty acid synthesis, Acyl‐coA synthetase
short‐chain family member (ACSS2). It was noteworthy that though
ACLY was overexpressed, the expression of the mitochondrial fatty
acid transporter CPT1 was also significantly upregulated at transcript
level as well (Figure 2b). There was no cellular accumulation of lactate
in BIO‐treated DPSCs (Figure 2a). However, in these conditions there
was a clear upregulation of LDHB and PDHB, and a downregulation of
LDHA transcript expression (Figure 2b). The expression of SLC16A1/
MCT1 was also significantly enhanced at mRNA level in DPSCs
following the BIO treatment (Figure 2b). We also tested the expression
of enzymes LDHA, LDHB, and HK2 by WB. We confirmed previous
findings by detecting increased levels of LDHB and decreased levels of
LDHA, whereas no significant changes were observed in HK2 in BIO‐
treated DPSCs (Figure 2c).
3.3 | Exposure to human recombinant WNT‐3A for
48 hr increases glucose utilization and the expression
of genes promoting mitochondrial TCA activity and
lipid biosynthesis in DPSCs
To ensure that the effects induced by BIO could be specifically
attributed to the activation of canonical Wnt signaling pathway
(Famili et al., 2015; Zhang et al., 2009) we also used WNT‐3A, a well‐
described prototypical canonical Wnt activator ligand. After the
treatment of DPSCs with WNT‐3A, we observed some of the same
effects found following the BIO treatment, with a higher consump-
tion of glucose (64.8% ± 11.7%; p = 0.004) and glutamate
(68.2% ± 3.1%; p = 0.003, respectively) with respect to control DPSC
levels. We also found an increase in choline consumption
(22.4% ± 15.2%; p = 0.036), although the levels of PC and GPC were
F IGURE 2 Wnt activation by BIO increases glucose utilization
and the expression of enzymes involved in mitochondrial TCA
metabolism and lipid biosynthesis in DPSCs. (a) NMR analysis
revealed differences in the levels of lactate, glutamine, GPC, and
glucose following BIO exposure. (b) Q‐PCR analysis confirmed an
increase in PKM2, LDHB, PDHA, PDHB, SLG16A, ACSS2, ACLY, and
CPT1A expression between control (MBIO) and BIO conditions. Data
are normalized to reference β‐ACTIN and GAPDH levels, and
presented as the mean + SEM (n = 6). The dashed line represents
normalized gene expression to control conditions. (c) Representative
WB showing an increase in LDHB, and a decrease in LDHA protein
levels. No changes were observed HK2 protein expression. β‐ACTIN
was used as a protein loading control. *p < 0.05; **p < 0.01;
***p < 0.001. U‐Mann Whitney test. BIO, 6‐bromoindirubin‐3′‐oxine;
DPSCs, dental pulp stem cells; GPC, glycerophosphocoline; NMR,
nuclear magnetic resonance; q‐PCR, quantitative polymerase chain
reaction; TCA, tricarboxylic acid cycle
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not significantly affected (Figure 3a). By qPCR we detected an
upregulation in the expression of some key gene markers for
glycolysis (HK2), TCA cycle (PDHB), lactate transporter (SLC16A1/
MCT1), pyruvate synthesis (LDHB), and acetyl‐coA and fatty acid
biosynthesis (ACLY; ACCSS2 respectively) in DPSCs (Figure 3b). Most
of these changes were consistent with what was observed in BIO
conditions. CPT1A gene expression was again found to be signifi-
cantly increased. Assessment of protein expression levels for LDHA,
LDHB, and HK2 by WB also confirmed a clear upregulation of HK2
and LHDB enzymes, in WNT‐3A‐treated DPSCs (Figure 3c).
3.4 | Wnt activation increases cellular reducing
power and the amount of NAD+ and NADH in DPSCs
As the metabolic and gene expression profile of DPSCs was altered
after Wnt/Notch modulation, we tested whether the overall reducing
power of DPSCs would be affected in these conditions as well. To
asses this hypothesis, first, we measured the levels of reduced NADH
and oxidized NAD+ in DPSC cultures subjected to DAPT/BIO/WNT‐
3A treatments. We found that reduced NADH levels increased
significantly when DPSCs were exposed to the recombinant protein
WNT‐3A, compared with controls (2.3 µM ± 0.1 µM; p = 0.018). The
levels of the oxidized NAD+ form were also found to be increased,
suggesting that this reducing power was being actively used by the
cells (Figure 4a). NADH levels were not affected in DAPT‐treated
cells, and they were found to be increased, although not significantly
(p = 0.105), in BIO‐treated cells (Figure 4a). Then, as a confirmation
for these results, we used Alamar Blue to assess the overall reducing
power of DPSCs subjected to different treatments (Figure 4b).
Alamar Blue is a general indicator of cellular reducing power because
it can react with different reduced nucleotide species such as
NADPH, NADH, and FADH2. Quantification of Alamar Blue
absorbance determined that BIO (193.2% ± 22.7%; p = 0.046) and
WNT‐3A‐treated DPSCs (276.9% ± 24.3%; p = 0.024) presented an
increased reducing power respect to control conditions, whereas the
reducing power was significantly lower in DPSCs treated with DAPT
(30.7% ± 14.3%; p = 0.001).
3.5 | Wnt activation induces hyperpolarization of
mitochondria of DPSCs
To study whether Notch and Wnt signaling could also affect the
energetic state of mitochondria, we first assessed the mitochondrial
potential by measuring the uptake of the fluorescent cationic lipid
species tetramethyl‐rhodamine ethyl ester (TMRE) by live DPSCs
that were treated with DAPT, BIO, and WNT‐3A. Incubation with
200 nM TMRE revealed the mitochondrial morphology and localiza-
tion in DPSCs in red fluorescence. TMRE fluorescence was increased
in BIO and WNT‐3A treated DPSCs (Figure 5a–c). The increased
TMRE uptake was confirmed by fluorescence quantification (Figure
5d). Thus, WNT‐3A‐treated DPSCs increased significantly their
mitochondrial membrane potential with respect to control DPSCs
(124.7% ± 1.1%; p = 0.022; Figure 5d). However, results of DC‐FDA
assays did not show any significant differences in ROS production
after these treatments. Normalized DC‐FDA fluorescence levels in
treated DPSCs with respect to controls were 83.3% ± 14.3% for BIO
and 91.5% ± 15.1% for WNT‐3A, respectively (n = 20). Instead,
following treatment with 0.5%, 1%, and 1.5% H2O2 (30min) the
DC‐FDA signal in DPSCs was more than four‐fold higher for 0.5%
H2O2 (430% ± 29%), and was more than two orders of magnitude
increased in the other two conditions (23092% ± 161.7%;
26070% ± 126%).
F IGURE 3 Wnt activation by WNT‐3A increases glucose
utilization, and the expression of enzymes involved in TCA
metabolism and lipid biosynthesis in DPSCs. (a) NMR analysis
revealed differences in the levels of glutamate, choline, and glucose
following WNT‐3A exposure. (b) Q‐PCR showing relative differences
on expression of HK2, PKM2, LDHA, LDHB, PDHB, SLC16A1, ACSS2,
ACLY, and CPT1. Data are normalized to reference β‐ACTIN and
GAPDH levels and represented as the mean + SEM (n = 6). The dashed
line represents normalized gene expression to control conditions. (c)
Representative WB showing an increase in LDHB and HK2 protein
expression. β‐ACTIN was used as a protein loading control. *p < 0.05;
**p < 0.01; ***p < 0.001. U‐Mann Whitney test. DMSO,
dimethylsulfoxide; DPSCs, dental pulp stem cells; NMR, nuclear
magnetic resonance; q‐PCR, quantitative polymerase chain reaction;
TCA, tricarboxylic acid cycle
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3.6 | Wnt activation induces the overexpression of
mitochondrial electron transport chain (ETC) genes,
but not ATP synthase genes in DPSCs
To estimate ETC activity in Wnt‐activated DPSCs, we tested the
expression of some genes coding for some mitochondrial ETC
complex subunits by qPCR. We observed increased levels of
transcript expression in most of the cytochrome C oxidase (complex
IV) subunits tested: COX4A.i1, COX6c, COX7a, and COX7c, and also
in the NADH‐Ubiquinone oxidoreductase (complex I) subunits
NDUFS1 and NDUFS2 in DPSCs treated with BIO and/or WNT‐3A
(Figure 5e,f). Interestingly, some of these subunits were also
upregulated in the case of DAPT treatment (Figure 5e,f). Finally,
the assessment of expression levels of mitochondrial ATP synthase
subunits ATP5a, ATP5e, and ATP5b provided us with information
about the utilization of the mitochondrial proton gradient to produce
ATP. Interestingly, there was no increase in the expression of ATP
synthase subunits in either BIO or WNT‐3A‐treated DPSCs
(Figure 5g), despite a clear upregulation of the expression of ETC
complexes and an increased mitochondrial membrane potential in
these conditions. A significant increase in ATP synthase subunit
expression was only found in cells treated with DAPT (Figure 5g).
3.7 | Wnt activation promotes lipid biosynthesis
and accumulation in DPSCs
To assess whether the treatments with DAPT, BIO, and WNT‐3A were
inducing changes in the cytoplasmic lipid content in DPSCs, we
performed a Nile Red staining. The treatment with WNT‐3A signifi-
cantly increased lipid accumulation in DPSCs, almost two times as much
comparing with control (180.% ±19.4%; p =0.005; Figure 6c,g). As a
positive control, we used sister cultures of DPSCs which underwent an
adipogenic pharmacological treatment, which presented a roughly
three‐fold increase in Nile Red fluorescence compared with the
nontreated cells (Figure 6f,g). Cells treated with DAPT showed a
nonsignificant reduction in Nile Red staining (Figure 6b,g).
3.8 | Wnt‐activated DPSCs overexpress
β‐oxidation enzymes at mRNA level
Mitochondrial β‐oxidation of fatty acids provides for molecules of
acetyl‐coA ready to enter the TCA cycle, whereas simultaneously
generating reducing power (Giudetti, Stanca, Siculella, Gnoni, &
Damiano, 2016). A limiting step in this process is the transport of
fatty acids to mitochondria, which is catalyzed by the carnitine
shuttle, in which CPT1 critically participates. Since we had demon-
strated that DPSCs treated with BIO or WNT‐3A accumulated
cellular lipids, whereas also significantly overexpressed CPT1 at
mRNA level, we examined whether transcript expression for
β‐oxidation enzymes would also be somehow affected in these
conditions. Interestingly, an upregulation of expression was
found for acyl‐coA dehydrogenase medium chain (ACADM) and
hydroxyacyl‐CoA dehydrogenase (HADHA) genes in BIO and WNT‐
3A‐treated DPSCs (Figure 6h).
4 | DISCUSSION
DPSCs are a promising source of pluripotent‐like stem cells for cell
therapy, which apart from being easily accessible, possess a
significant capacity for in vitro expansion, have nontumorigenic
phenotypes and a greater multilineage differentiation potential than
other tissue‐specific stem cells (Atari et al., 2012; Kerkis et al., 2006;
Rosa, Dubey, Islam, Min, & Nör, 2016). Compared with pluripotent
stem cells (PSCs), embryonic stem cells (ESCs), and induced
F IGURE 4 Wnt activation increases reducing power in DPSCs. (a)
NADH and NAD+ assay revealed differences in the cellular
concentration of NADH and NAD+ in DPSCs following DAPT, BIO,
and WNT‐3A exposure. (b) Alamar Blue detection confirmed that
reducing power in DPSCs was higher in BIO and WNT‐3A conditions.
(c) Quantification of Alamar Blue detection at 600 nm in DMSO,
DAPT, MBIO, BIO, and WNT3‐A‐treated DPSCs. Data are presented
as the mean + SEM (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001. U‐Mann
Whitney test. BIO, 6‐bromoindirubin‐3′‐oxine; DAPT, N‐[N‐(3,5‐
difluorophenacetyl)‐L‐alanyl]‐S‐phenylglycine t‐butyl ester; DMSO,
dimethylsulfoxide; DPSCs, dental pulp stem cells; MBIO, methyl‐6‐
bromoindirubin‐3′‐oxine
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pluripotent stem cells (iPSCs), DPSCs do not pose ethical or safety
issues. In a previous report, we demonstrated that the stemness of
DPSCs could be enhanced by a controlled activation of Notch/Wnt
signaling pathways, which are functionally interconnected in these
cells. Thus, a short (48 hr) pharmacological Wnt activation by BIO or
WNT‐3A caused an important increase in the expression of
pluripotency core factors in DPSCs (Uribe‐Etxebarria et al., 2017).
This kind of gentle approach to enhance stemness without relying on
traditional nuclear reprogramming methods may prove beneficial to
fully exploit the capabilities of DPSCs and other tissue‐specific stem
cells.
Over the last few years, metabolism has entered the stage as a
fundamental regulator of pluripotency (Folmes et al., 2011; Mathieu
& Ruohola‐Baker, 2017). In fact, activation of glycolysis pathways is
known to enhance somatic cell reprogramming efficiency (Folmes,
Dzeja, Nelson, & Terzic, 2012) and pharmacological activation of
glycolysis, in combination with other small compounds, allows for a
reduction of the traditional recipe of Yamanaka factors for nuclear
F IGURE 5 Wnt activation hyperpolarizes mitochondria and increases the levels of mRNA expression of ETC subunits, but not ATP synthase
subunits, in DPSCs. (a–c) TMRE‐loaded DPSCs grown with DMSO, BIO, and WNT‐3A treatment of 48 hr. Scale bar: 20 µm. (d) Quantification of
relative TMRE/Calcein fluorescence. Data are presented as mean + SEM (n =12). (e–g) Q‐PCR showing relative differences in cytochrome C oxidase
subunits (COX4A1, COX6C, COX7A2, and COX7C), ATP synthase subunits (ATP5A1, ATP5B, and ATP5E), and NADH‐ubiquinone oxidoreductase
subunits (NDUFS1 and NDUFS2). Data are normalized to reference β‐ACTIN and GAPDH levels and represented as the mean + SEM (n = 6). *p < 0.05;
**p < 0.01; ***p < 0.001. U‐Mann Whitney test. ATP, adenosine triphosphate; BIO, 6‐bromoindirubin‐3′‐oxine; DAPT, N‐[N‐(3,5‐difluorophenacetyl)‐L‐
alanyl]‐S‐phenylglycine t‐butyl ester; DMSO, dimethylsulfoxide; DPSCs, dental pulp stem cells; MBIO, methyl‐6‐bromoindirubin‐3′‐oxine; mRNA,
messenger RNA; q‐PCR, quantitative polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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reprogramming to a simplified version containing just OCT‐4 (Zhu
et al., 2010). Consistently, pharmacological inhibition of glycolysis
results in a reduced reprogramming efficiency (Folmes et al., 2011).
This evidence illustrates how metabolic plasticity can facilitate (or
impair) stemness. In fact, the differentiation of pluripotent cells and
the reprogramming of somatic cells often involve metabolic switches
at very early stages, before changes in phenotype and/or the
expression of pluripotency core factors can be yet observed (Folmes
et al., 2011).
The current prevailing view acknowledges that fully differen-
tiated cells rely mainly on mitochondrial oxidative phosphorylation to
meet their energy demands, whereas noncommitted PSCs primarily
use glycolysis and production of lactate. This metabolic signature was
first described in cancer cells as “The Warburg Effect” (Vander
Heiden, Cantley, & Thompson, 2009; Warburg, 1956), and it was
later consistently observed in both ESCs and iPSCs (Mathieu &
Ruohola‐Baker, 2017; Varum et al., 2011). Following the DAPT
treatment, glucose was accumulated in DPSCs, suggesting a lower
utilization of this primary fuel for glycolysis. Consistently, also the
levels of lactate were found to be significantly lower than in control
samples. Interestingly, despite being the glycolysis inhibited, gluta-
mine and glutamate were not being used as alternative source of
energy following the DAPT treatment, since the levels of these amino
acids were not changed, with respect to control DPSCs.
F IGURE 6 Wnt activation promotes both lipid biosynthesis and oxidation in DPSCs. (a-f) Nile Red Staining revealed differences in the
accumulation of lipid droplets under BIO and WNT‐3A exposure. Scale bar = 20 µm. (g) Bar chart showing relative fluorescence of Nile Red in
DMSO, DAPT, MBIO, BIO, and WNT‐3A conditions. (h) Q‐PCR analysis showed an increase in ACADM and HADHA expression in WNT‐3A and
BIO‐treated cells. The data are normalized to reference β‐ACTIN and GAPDH levels and presented as the mean + SEM (n = 6). *p < 0.05;
**p < 0.01; ***p < 0.001. U‐Mann Whitney test. BIO, 6‐bromoindirubin‐3′‐oxine; DAPT, N‐[N‐(3,5‐difluorophenacetyl)‐L‐alanyl]‐S‐phenylglycine
t‐butyl ester; DMSO, dimethylsulfoxide; DPSCs, dental pulp stem cells; MBIO, methyl‐6‐bromoindirubin‐3′‐oxine; mRNA, messenger RNA;
q‐PCR, quantitative polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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In Wnt‐activated DPSCs, we observed an upregulation of glycolysis
after 48 hr. This was characterized by a decrease in cellular glucose
levels, assessed by NMR, and an increased expression of glycolytic
enzymes at both mRNA and protein level. However, WNT‐3A‐treated
DPSCs did not show the portrait of a classic Warburg effect, since most
of the glucose appeared to be directed to pyruvate and mitochondrial
acetyl‐coA synthesis, rather than towards the production of lactate. In
fact, lactate levels were not increased at all in Wnt‐activated DPSCs.
Furthermore, we found an overexpression of the membrane transporter
SLC16A1/MCT1, suggesting that lactate might even be taken up by
DPSCs as an alternative source of pyruvate. The overexpression of the
lactate‐to‐pyruvate converter enzyme LDHB and the downregulation of
expression of its antagonistic enzyme LDHA, at both gene and protein
levels, during both BIO and WNT‐3A treatment seem to add strong
support to this view.
If Wnt‐activated DPSCs were driving an enhanced glycolytic
input to feed the mitochondrial TCA cycle, as also suggested by the
overexpression of mitochondrial PDH complex subunits, and the
accumulation of cellular reducing power (NADH), then the question
became: With what purpose? It seemed that at least some of this
reducing power was being used by the mitochondrial ETC, as
suggested by the increased expression of some key Complex I and
Complex IV subunits. Consistently, mitochondria were hyperpolar-
ized in DPSCs exposed to BIO and WNT‐3A, with an about 25%
increased uptake of TMRE. However, this mitochondrial hyperpolar-
ization did not came along with a concomitant increase in the
expression of ATP synthase subunits, which suggested that the
accumulation of reducing power in these conditions was not being
primarily used to synthesize more ATP. The observation of
mitochondrial hyperpolarization is interesting, since this has also
been observed in other PSCs (Folmes et al., 2011). The mitochondrial
potential magnitude has been reported to be predictive of the
stemness of ESCs, where populations of high‐mitochondrial potential
ESCs were more prone to generating teratomas after transplanta-
tion, whereas low‐mitochondrial potential ESCs were found to be
pre‐committed for somatic differentiation (Schieke et al., 2008).
Recent evidence showed that maintenance of a high‐mitochondrial
membrane potential is required for a burst in ROS generation which
regulates cell proliferation by hypoxia inducible factor (HIF) expression
(Martínez‐Reyes et al., 2016). However, in our DPSC cultures we could
F IGURE 7 Representation of metabolic pathways and steps affected during Wnt activation in DPSCs. Wnt signaling activation by either
BIO or WNT‐3A increases glucose consumption by overexpression of glycolytic enzymes HK2 and/or PKM2. LDHA and LDHB participate
in lactate to pyruvate conversion. LDHB is overexpressed whereas LHDA is downregulated in Wnt‐activated DPSCs. Pyruvate
dehydrogenase complex subunits are also upregulated in BIO/WNT‐3A treated DPSCs, thus fueling the mitochondrial TCA cycle. These
“hyper‐energized” DPSCs show a net accumulation of lipids and a mitochondrial hyperpolarization. Overexpression of cytosolic ACLY and
ACSS2 enzymes suggests cataplerosis leading to cytosolic accumulation of acetyl‐coA, which could be then used for lipid biosynthesis.
Meanwhile, mitochondria consume amino acids such as glutamine and glutamate to replenish TCA metabolites in a coordinated cycle of
cataplerosis and anaplerosis. Cytosolic fatty acids also appear to participate in this process of TCA fueling, as suggested by the
overexpression of CPT1 and β‐oxidation enzymes at mRNA level. DPSCs reprogrammed with BIO or WNT‐3A thus show a boost in
glycolysis without the characteristic lactate accumulation observed in the classic Warburg effect. BIO, 6‐bromoindirubin‐3´‐oxine; DPSCs,
dental pulp stem cells; TCA, tricarboxylic acid cycle [Color figure can be viewed at wileyonlinelibrary.com]
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not detect any significant increase in ROS production by DC‐FDA
fluorimetric assays after the treatment with BIO or WNT‐3A. Interest-
ingly, experiments of somatic cell reprogramming to PSCs at very early
stages showed that the increase in glycolysis associated with nuclear
reprogramming was at first accompanied by a burst in ETC activity,
before switching to a classic Warburg‐like glycolytic metabolism
(Hawkins et al., 2016; Kida et al., 2015). In our experimental model,
DPSCs were exposed to Wnt activators and the cell phenotype was
assessed short‐term, after only 48 hr, a time frame which could easily
correspond with such early reprogrammed cells. Other studies have
reported that a functional ETC is essential for maintaining pluripotency
(Zhang et al., 2016a), and that disruption of mitochondrial dynamics could
directly impact reprogramming efficiency (Facucho‐Oliveira, Alderson,
Spikings, Egginton, & St John, 2007; Vazquez‐Martin et al., 2012).
Altogether, mitochondrial changes in our model of DPSCs seem to
correspond with a stemness‐associated metabolic plasticity, although a
possible involvement of ROS signaling in this context should be further
clarified.
Accumulation of reducing power in DPSCs renders cells “hyper‐
energetic,” with a high capacity for cellular biosynthesis. TCA cycle
intermediaries such as citrate and oxaloacetate are used for the de
novo synthesis of lipids and nucleotides, which could provide cells
with a source of energy and metabolites when differentiation signals
begin (Chandel et al., 2016). In fact, another of the most interesting
findings of the present work is that DPSCs were accumulating
cytoplasmic lipid droplets after Wnt activation, as assessed by Nile
Red staining. Lipid biosynthesis requires cytosolic acetyl‐coA, which
is primarily derived from a cytosolic export of mitochondrial citrate,
to provide for an increase in cellular reducing power and release of
biosynthesis metabolites in a process known as cataplerosis (Owen,
Kalhan, & Hanson, 2002). Then, a critical metabolic reaction is
catalyzed by the ACLY enzyme, which transforms this citrate to
acetyl‐coA, thus linking carbohydrate and lipid metabolism (Wellen
et al., 2009). Importantly, ACLY expression was found to be clearly
upregulated in DPSCs after BIO and WNT‐3A treatment. In this
context, the accumulation of cytosolic acetyl‐coA could serve two
main purposes: (a) To provide a primary substrate for lipid
biosynthesis, and (b) to provide a substrate for histone acetylation,
which has been shown necessary to maintain pluripotency (Mous-
saieff et al., 2015b). In fact, compelling evidence indicates that during
F IGURE 8 The modulation of DPSC stemness by Notch and Wnt signaling comes associated with a deep metabolic remodeling. During the first
48 hr of treatment with BIO or WNT‐3A, DPSCs show an atypical Warburg effect, boosting glycolysis but also mitochondrial TCA activity. These
metabolic changes are associated with an increase in the expression of pluripotency core factors, and the stemness of DPSCs. DPSCs in these conditions
accumulate large amounts of reducing power, and cytoplasmic lipids. Understanding metabolic changes linked to DPSC reprogramming could be of great
interest to make the best use of DPSCs for cell therapy. BIO, 6‐bromoindirubin‐3′‐oxine; DPSCs, dental pulp stem cells; TCA, tricarboxylic acid cycle
[Color figure can be viewed at wileyonlinelibrary.com]
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early stages of differentiation of human ESCs, cytosolic acetyl‐coA
levels drop and this was associated with histone deacetylation and
spontaneous cell differentiation. In contrast, a rise of cellular acetyl‐
coA levels was linked with maintenance of pluripotency (Moussaieff
et al., 2015b).
Thus, in view of our results and despite the fact that we could
not actually measure acetyl‐coA levels in our model, in all
likelihood cataplerosis was occurring in DPSCs after Wnt‐activa-
tion. This would clearly support lipid biosynthesis as storage of fuel
reserves to prepare for subsequent differentiation stimuli demand-
ing a fast production of ATP and metabolites, but in addition, it
could also mediate histone acetylation related to an enhanced
stemness (Martínez‐Reyes et al., 2016; Moussaieff, Kogan, &
Aberdam, 2015a). Interestingly, together with an increased lipid
biosynthesis, we detected reduced levels of glutamate and
glutamine in Wnt‐activated DPSCs, indicating compensatory
anaplerosis to sustain high TCA cycle activity levels. Finally, some
of the fatty acids generated by DPSCs after Wnt activation were
also being transported to mitochondria for β‐oxidation, as
suggested by the increased expression of CPT‐1 and other genes
(ACADM and HADHA) coding for β‐oxidation enzymes. These results
feature a complex and coordinated cycle of cataplerosis and
anaplerosis to support the activity of the mitochondrial TCA cycle,
and thus generate a large reducing power and a mitochondrial
hyperpolarization in DPSCs. The main findings of the present work
are summarized in Figures 7,8.
In conclusion our data show that enhancement of DPSC stemness
by short‐term Wnt signaling activation for 48 hr comes along with a
profound metabolic remodeling, featuring a boost of glycolysis but
also of mitochondrial TCA activity. This metabolic plasticity bears
some resemblance with other models of somatic cell reprogramming
at very early stages, where a distinct involvement of mitochondrial
potential and oxidative phosphorylation have also been reported, in
contrast to the classically portrayed Warburg effect featured by
lactate accumulation. We associate these changes to a transient
hyper‐energetic priming stage, where DPSCs accumulate a large
reducing power for biosynthesis. Interestingly, DPSCs also generated
cytoplasmic lipid reserves, a process likely associated with cata-
plerosis. Altogether, we showed that the increase in pluripotency
core factor expression observed after Wnt activation in DPSCs was
mirrored by important changes in both glycolytic and oxidative
metabolism, suggesting that stemness and metabolic plasticity are
intimately related. A characterization and modulation of these
metabolic changes could be of great interest to make the best use
of DPSCs and their stemness/differentiation capabilities regarding
cell therapy (Table A.1).
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TABLE A.1 Table of primers used in RT‐PCR with sequences, annealing temperature, and amplicon size
Primers Sequence 5′– 3′ Annealing (°C) Amplicon (bp)
β‐ACTIN PubMed Gene ID: 60 Upstream GACGACATGGAGAAAATCTG 59.7 131
Downstream ATGATCTGGGTCATCTTCTC 58
GAPDH PubMed Gene ID: 2597 Upstream GTTTTGCGTCGCCAG 60.3 139
Downstream TTGATGGCAACAATATCCAC 60.8
Hexokinase2 (HK2) PubMed Gene ID: 3099 Upstream GAAAGCAACTGTTTGAGAAG 56.7 162
Downstream CAATGTCTGAGATGTCTTTGG 59.8
Pyruvate kinase isoenzyme M2 (PKM2) PubMed Gene
ID: 5315
Upstream ATGTTGATATGGTGTTTGCG 60.9 142
Downstream ATTTCATCAAACCTCCGAAC 60.4
Lactate dehydrogenase A (LDHA) PubMed Gene ID: 3939 Upstream CACCATGATTAAGGGTCTTTAC 58.9 87
Downstream AGGTCTGAGATTCCATTCTG 58.2
Lactate dehydrogenase B (LDHB) PubMed Gene ID: 3945 Upstream TTGAAAGTGCCTATGAAGTC 56.9 152
Downstream ATTCTCAATGCCATACATCC 58.8
Pyruvate dehydrogenase A1 (PDHA1) PubMed Gene ID: 5160 Upstream CAGCACTGATTACTACAAGAG 54.2 120
Downstream CCCTTCCCAGATCTACAATAG 59.1
Pyruvate dehydrogenase B (PDHB) PubMed Gene ID: 5162 Upstream GAGGTGATAAATATGCGTACC 57.6 92
Downstream CCTTCCACAGTTACAAGATG 57.2
Pyruvate dehydrogenase X (PDHX) PubMed Gene ID: 8050 Upstream GCAAATGCCAGATGTTAATG 60.6 147
Downstream GCAATTTCCTGGATACCTTTAG 60.4
ATP citrate lyase (ACLY) PubMed Gene ID: 47 Upstream TGTAGTGACCAAAGATGGAG 57.7 81
Downstream TTCACTTTGCAGATGTAGTC 55.3
Acyl‐Coa synthetase short‐chain family member 2 (ACSS2)
PubMed Gene ID: 55902
Upstream GCTCAAGAAGCAGATTAGAG 56 137
Downstream CATGGTCATTCTGAGCAATC 60.7
Carnitine palmitoyltransferase 1A (CPT1A) PubMed Gene
ID: 1374
Upstream AAGTTTTATCTGAGCCTTGG 57.5 195
Downstream AGAACTTGGAAGAAATGTGG 58.2
Monocarboxylate transporter 1 (MCT1/SLC16A1) PubMed
Gene ID: 6566
Upstream TATTGGAGTCATTGGAGGTC 59 194
Downstream TTAGAAAGCTTCCTCTCCATC 59.1
Hes family bHLH transcription Factor 1 (Hes1) PubMed Gene
ID: 3280
Upstream GGTACTTCCCCAGCACACTT 59 137
Downstream GAAGAAAGATAGCTCGCGG 57.7
Lymphoid enhancer binding Factor 1 (Lef1) PubMed Gene ID:
51176
Upstream TGCCAAATATGAATTAACGACCCA 59 151
Downstream GAGAAAAGTGCTCGTCACTGT 58.5
Cytochrome c oxidase subunit 6C (COX6C) PubMed Gene
ID: 1345
Upstream TTGTATAAGTTTCGTGTGGC 57.7 117
Downstream TACACTCTGAAAGATACCAGC 56.1
Cytochrome c oxidase subunit 7A2 (COX7A2) PubMed Gene
ID: 1347
Upstream AAATAAAGTTCCGGAGAAGC 58.9 123
Downstream GTTCCACCAACTGTAAGAATC 57.6
Cytochrome c oxidase subunit 7C (COX7C) PubMed Gene
ID: 1350
Upstream GAATTTGCCATTTTCAGTGG 61.9 77
Downstream TAGCAAATGCAGATCCAAAG 60.4
Cytochrome c oxidase subunit 4I1(COX4I1) PubMed Gene
ID: 1327
Upstream ATTGAAGGAGAAGGAGAAGG 58.9 82
Downstream CTCCTTGAACTTAATGCGATAC 59.3
Cytochrome c oxidase subunit 6B1 (COX6B1) PubMed Gene
ID: 1340
Upstream AAGACATGGAGACCAAAATC 58.9 149
Downstream AGAGATATCGCCTCCTTTAG 57.6
ATP synthase F1 complex subunit alpha (ATP5A1) PubMed Upstream ACGTTTCAATGATGGATCTG 60 111
(Continues)
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Primers Sequence 5′– 3′ Annealing (°C) Amplicon (bp)
Gene ID: 11946 Upstream TCTGCATCTGTAAGTCTCTTC 56.2
ATP synthase F1 complex, beta subunit (ATP5B) PubMed Gene
ID: 11947
Upstream TACCACCAATTCTAAATGCC 58.9 85
Downstream GTGCTCTCACCCAAATG 57.5
ATP synthase F1 complex subunit epsilon (ATP5E) PubMed
Gene ID: 67126
Upstream CTCAGCTACATCCGATACTC 56.4 154
Downstream CATTTCAAGCTTTAGTCAGGG 60.3
NADH ubiquinone oxidoreductase core subunit S1 (NDUFS1)
PubMed Gene ID: 4719
Upstream TTACTTCCAGCAAGCAAATG 60.5 123
Downstream GAGGCTCTGCTAATTGAATC 58.1
NADH ubiquinone oxidoreductase core subunit S2 (NDUFS2)
PubMed Gene ID: 4720
Upstream GATGTTTGAGTTCTACGAGC 56.5 185
Downstream GATTTCGCCAGATCCTATTG 61
Acyl‐CoA dehydrogenase medium chain (ACADM) PubMed
Gene ID: 34
Upstream TACTTGTAGAGCACCAAGC 55.5 118
Downstream GTATTTCGACGACCAGAATC 58.6
Hydroxyacyl‐CoA dehydrogenase trifunctional multienzyme
complex subunit alpha (HADHA) PubMed Gene ID: 3030
Upstream ACTAAAACCTCCAGAGGAAC 56.4 123
Downstream GTCAATTTTTCCACCAATCC 60.6
Note: RT‐PCR: real‐time polymerase chain reaction.
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